Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284986 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants
A Phase 2 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00284986 is a Phase 2 study that has completed, run by Mesoblast. The registered enrollment target is 11 participants.
The verdict
NCT00284986, a Phase 2 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) in participants experiencing treatment-refractory acute GVHD, Grades III-IV, that is refractory to standard first-line therapies and at least one second-line therapy.
Interventions
- DRUG Prochymal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-11-18 |
| Est. Completion | 2007-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284986
The ClinicalTrials.gov registry entry for NCT00284986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prochymal is the first listed.
NCT00284986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00284986 about?
NCT00284986 is a clinical study titled "Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants". This study is designed to evaluate the safety and efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) in participants experiencing treatment-refractory acute GVHD, Grades III-IV, that is refractory to standard first-line therapies and at least one second-line therapy.
What is the current status of trial NCT00284986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2005-11-18. Estimated completion is 2007-02-08.
What interventions are being tested in trial NCT00284986?
The interventions under investigation include: Prochymal (DRUG).
Who is sponsoring clinical trial NCT00284986?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.